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Abstract 
 
Cephalexin is a first generation cephalosporin widely used in rabbits. Its spectrum includes Pasteurella 
multocida and Staphylococcus aureus. These bacteria, together with Bordetella bronchiseptica, are the 
main cause of respiratory infections. Although many textbooks on rabbit therapeutics report the use of 
cephalexin, including administration schedules, there are not published papers on the pharmacokinetics 
of cephalexin after IV and IM administration to rabbit. Therefore, the objective of the present study was 
to describe cephalexin disposition in rabbits after intravenous and single and multiple intramuscular 
administrations. Three administration schedules were studied: single IV administration (10 mg/kg), 
single IM administration (10 mg/kg) and multiple IM administration (2.5 mg/kg/6). Serial blood 
samples were collected over a 24 h period. Cephalexin plasma concentrations were determined by 
microbiological method using Kocuria rhizophila ATCC 9341 as microorganism test. No statistical 
differences were observed between routes of administration for any of the estimated PK parameters. The 
unique difference was observed on bioavailability between intramuscular administration schedules. 
Elimination half-life was 1.45, 1.09 and 1.91 h for the single IV, single IM and multiple IM administration, 
respectively. Bioavailability after single and multiple IM administration was 47 and 97.5%, respectively. 
After multiple IM administration maximum and minimum plasma concentration at steady state were 
2.77 and 0.34 µg/ml, while Cmax after single IM administration was 9. 22 µg/ml. 
 
Considering that for betalactams the PK/PD breakpoint recommended for efficacy (T > MIC) should be 
50–80% and that the reported MIC for most gram-positive organisms and Pasteurella multocida is ≤1.0 
μg/ml, the present study demonstrates that a single IM dose of 10 mg/kg/24 h is enough to maintain 
therapeutic concentrations for a 24 hours period. When a 2.5mg/kg dose is used administration every 6 
hours is recommended.   
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Introduction 
 
Cephalexin is a first generation 
cephalosporin with high activity against 
Gram-positive cocci (staphylococci, 
streptococci) including many beta-lactamase-
producing strains, some Gram-negative 
Enterobacteriaceae and anaerobes (Prescott, 
2006). Cephalexin is, due to its high efficacy 
against Pasteurella multocida and 
Staphylococcus aureus, commonly used in 
rabbit for the treatment of respiratory 
infections (Rougier et al., 2006).  These 
bacterial agents, together with Bordetella 
bronchiseptica, are the main cause of 
respiratory infections, which may give 
symptoms such as sneezing, coughing, nasal 
discharge and lethargy. They are also 
involved in formation of abscesses in 
subcutaneous tissues, behind the eye bulb or 
in internal organs as well as inflammation of 
the mucus membranes of the eyes and in the 
middle ear. 
 
The reported minimum inhibitory 
concentration (MIC) for most gram-positive 
organisms and Pasteurella multocida is 
≤1.0 μg/mL, while for susceptible gram-
negative organisms (E. coli, and Klebsiella 
pneumoniae) it may be as high as 8 μg/ml 
(Prescott, 2006).  
 
As for other betalactam antibiotics, 
cephalexin antibacterial activity is time 
dependent, i.e. time free drug concentration 
remains above the MIC (T > MIC) being the 
PK/PD parameter that relates better with 
clinical efficacy (Toutain et al., 2002; 
McKellar et al., 2004). 
  
Cephalexin, in most species, is administered 
by oral route. However, in rabbits disruption 
of the normal enteric flora, with the 
consequent overgrowing of toxin producing 
Clostridium, is a common side effect for this 
route of administration for a number of 
antimicrobials, included cephalexin; 
therefore its use is not advisable (Carman, 
1993).  
 
Although many textbooks on rabbit 
therapeutics report the use of cephalexin 
(Morris, 1995; Ivey and Morrisey, 2000; 
Harcourt-Brown, 2002; Richardson, 2003; 
Saunders and Davies, 2005; Meredith and 
Flecknell, 2006), there are not published 
papers on the pharmacokinetics of 
cephalexin after IV and IM administration. 
Therefore, the objective of the present study 
was to describe the plasma disposition of 
cephalexin after intravenous and single and 
multiple intramuscular administration to 
adult rabbits.   
 
Materials and Methods 
 
The study was carried out in twelve healthy 
New Zealand White rabbits of weight 3.0- 3.5 
kg. They were maintained in cages of 60 cm x 
60 cm x 90 cm with free access to water and 
to a commercial diet (Gepsa Feeds, Pilar 
Group, Argentina).  
 
All animal procedures were approved by the 
Institutional Animal Care and Use Committee, 
School of Veterinary, University of La Plata, 
Argentina. 
 
Animals were divided into three groups: 
Group 1 (n=4) received cephalexin lysine salt 
(cefalexina, Laboratorio Richet, Argentina) 
intravenously at a dose rate 10 mg/kg, group 
2 (n=4) received the same dose but 
intramuscularly and group 3 (n=4) received 
also intramuscularly a total of four 2.5 mg/kg 
doses of cephalexin every 6 hours. 
 
Blood samples (0.4 ml) were collected in K-
EDTA, through a 24G x ¾” intravenous 
catheter (Introcan®, Braun Aß, Germany) 
placed in the marginal ear vein, at 3, 6, 9, 12, 
18 and 24 hours post-administration. For the 
intravenous administration two additional 
samples were withdrawn at 0.5 and 1 h post-
administration. 
 
Cephalexin plasma concentration was 
determined by microbiological assay (Bennet 
et al.,1966) using Kocuria rhizophila, 
formerly classified as Micrococcus luteus 
(American Type Culture Collection 9341) as 
test microorganism.  
 
Each sample was measured in triplicate and a 
standard curve was prepared using normal 
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rabbit plasma. Serial twofold dilutions from 
25 to 0.39µg/ml were used. Inhibition zones 
around the sample wells were measured with 
a digital calliper and compared with 
inhibition zones produced by the standards. 
 
The limit of detection and quantification of 
the method were 0.39 and 0.78 µg/ml, 
respectively. The method was linear between 
0.39 and 25 µg/ml (r = 0.9984). Inter and 
intra-assay coefficients of variation were 9.39 
and 4.87 %, respectively. 
 
Individual cephalexin  plasma concentration 
vs. time curves were analyzed by non-linear 
least square regression analysis using 
PCNonlin (SCI Software, Lexington, USA), 
applying a one compartment open model 
with first order absorption and elimination. 
Initial estimates were determined using the 
residual method (Gibaldi and Perrier, 1982) 
and refitted by non linear regression. Most 
pharmacokinetic parameters were calculated 
using classic equations associated with 
compartmental analysis (Gibaldi and Perrier, 
1982). 
 
Pharmacokinetic parameters are expressed 
as median and range. Main parameters for 
each animal were statistically compared for 
the three administration methods applying 
Kruskall Wallis test. Differences were 
considered statistically significant when p ≤ 
0.05. 
 
Results and Discussion 
 
The microbiological assay used in this study 
was appropriate for the quantification of 
cephalexin concentrations, as no active 
metabolite has been identified in rabbits for 
this drug; therefore, plasma concentration 
data and pharmacokinetics correlate 
accurately with total antimicrobial activity. 
Besides, the good correlation between 
microbiological assay and other analytical 
methods, including HPLC has been reported 
(Steppe et al., 2003). 
 
Adverse effects were not observed during or 
following cephalexin IV or IM administration 
in any of the experimental animals.  
 
Cephalexin mean plasma concentration–time 
curves following IV and IM administrations 
are shown in Fig. 1.  Estimated 
pharmacokinetic parameters for both routes 
are summarized in Table 1.  
 
 
 
 
 
Fig. 1. Mean (±SD) Cephalexin Plasma Concentrations after Intravenous and Single and 
Multiple IM Administration to Rabbits (N=4) 
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Table 1: Median (Range) Pharmacokinetic Parameters of Cephalexin after Intravenous and 
Single and Multiple Intramuscular Administration to Rabbits (N=4) 
 
PK PARAMETER SINGLE IV DOSE 
(10 mg/kg) 
SINGLE IM DOSE 
(10 mg/kg) 
MULTIPLE  IM DOSE 
(2.5 mg/kg/6h) 
Kel (1/h) 0.92(0.36-1.63) 0.63 (0.10-3.55) 0.36 (0.25-0.46)  
Ka (1/h) NA 0.83 (0.27-16.99) NA* 
AUC(0-∞) (µg/h/ml) 103.02 (94.77-144.99) 64.26 (27.5-90.80) 25.41 (20.38-47.05) 
T½elim (h) 1.45 (0.42-2.57) 1.09 (0.20-6.74) 1.91 (1.52-2.74) 
T½ (a) (h) NA 1.12 (0.04-2.60) NA 
Cp (0) -Cmax (µg/ml) 85.02 (27.85-236.78) 9.22 (2.74-16.70) NA 
Tmax (h) NA 1.09 (0.30-1.40) NA 
ClB (ml/kg/h) 0.10 (0.07-0.11) 0.06 (0.05-0.27) 0.08 (0.056-0.124) 
Vss- Vss/F (l/kg) 0.21 (0.04-0.36 ) 0.55 (0.04-3.53) 0.27 (0.12-0.48) 
F(%) NA 47.75 (31.40-76.00)** 97.51 (53.8-135.00)** 
Css (max) NA NA 2.77 (1.52-3.39) 
Css(min) NA NA 0.340.16-0.48 (0.16-0.48) 
RA NA NA 1.21 (1.06-1.31) 
T>MIC (h) 24 24 6 
 
Kel elimination rate constant; Ka absorption 
rate constant; AUC (0-∞) area under the plasma 
concentration vs. time curve from 0 to 
infinite;  t½ elimination half-life; t½ (a) 
absorption half-life; Cp (0) plasma 
concentration at 0 time ; Cmax maximum 
concentration; Tmax time of maximum 
concentration ClB body clearance; Vss volume 
of distribution;  F bioavailability; RA 
accumulation rate ;Css(max) maximum 
concentration at steady state; Css(min) 
minimum concentration al steady state. RA 
accumulation index T>MIC amount of time 
drug concentrations are maintained above 
an MIC of 1µg/ml 
 
* Since Ka>>Kel, e –Kat approaches zero, the 
original model equation     
becomes 
(Gunaratna, 2001)  
 
**p<0.05 
 
No statistical differences were observed 
between routes of administration for any of 
the estimated PK parameters, this could be 
consequence of the high inter-animal 
variation. Unique statistical significant 
difference was observed when comparing 
bioavailability after IM administrations. 
 
The most common route of administration 
for cephalexin in most species is the oral. 
Although, published data suggest actual or 
potential toxicity related to their use in 
rabbit, as well as in hamster and guinea pigs 
(Morris, 1995; Carman, 1993) .The 
mechanism of toxicity is related to the 
disruption of normal enteric flora and the 
consequent overgrowth of toxigenic 
Clostridium difficile and innocuum (Hara-
Kudo, et al., 1996).  
 
Another administration route that could be 
used in rabbits for cephalexin administration 
is the subcutaneous. However, it is important 
to highlight that dehydration, commonly 
observed in sick animals, can reduce the rate 
and extent of absorption of antimicrobials; 
this situation is not observed after IM 
administration (Ballard, 1968).   
 
After IM administration, bioavailability for 
the single administration was 47.75 %. This 
values is similar to that reported for dogs 
(60%) (Carli et al., 1999; Chicoine et al., 
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2009). After multiple administration 
bioavailability was higher (p<0.05),   this 
difference could be reflecting the 
improvement of absorption when small 
volumes are injected (Zuidema et al., 1994). 
 
Maximum plasma concentration (Cmax) after 
single IM administration was almost three 
times lower compared with values reported 
for the same dose in dogs (Silley et al., 1988). 
Comparison of Cmax after single IM 
administration with maximum concentration 
an steady state (Css(max)) after multiple 
administration, after correcting for dose 
difference, shows a higher value for the 
repeated administration schedule. This is 
reflecting the higher bioavailability of the 
latter schedule.   
 
No statistically significant differences 
between administration routes and 
administration schedules were observed in 
elimination half-life. This is consequence of 
the high inter-animal variation observed, 
especially, after IV and single IM 
administration. The estimated valueswere 
similar to that in other species such as, rat 
(Tsai et al., 2000) dog (Carli et al., 1999) and 
cat (Albarellos et al., 2011).  Accumulation 
index after multiple administrationswas 
closed to 1, reflecting cephalexin low 
accumulation capacity.Similar values are 
reported for humans after repeated oral 
administration (Pfeffer et al., 1977). 
 
The antibacterial activity of cephalexin 
depends on the amount of time drug 
concentrations are maintained above 
the MIC(T > MIC) for susceptible bacteria. 
Current recommendations for 
cephalosporins suggest that concentrations 
be maintained above the MIC for at least 50% 
of the dosing interval to achieve maximum 
activity (McKellar et al., 2004; Toutain et al., 
2002). Considering that the reported MIC for 
most gram-positive organisms 
and Pasteurella multocida is ≤1.0 μg/ml 
(Griffith and Black, 1970; Brown et al., 2004), 
the present study demonstrates that a single 
IM dose of 10 mg/kg/24 h is enough to 
maintain therapeutic concentrations for a 24 
hours period. When a 2.5mg/kg dose is used 
administration every 6 hours is necessary.   
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